Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2016 1
2017 1
2018 4
2019 6
2020 10
2021 13
2022 12
2023 13
2024 9
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671).
Proto C, Ganzinelli M, Manglaviti S, Imbimbo M, Galli G, Marabese M, Zollo F, Alvisi MF, Perrino M, Cordua N, Borea F, de Vincenzo F, Chella A, Cappelli S, Pardini E, Ballatore Z, Lucarelli A, Ambrosini E, Giuliano M, Pietroluongo E, Mulargiu C, Fabbri A, Prelaj A, Occhipinti M, Brambilla M, Mazzeo L, Beninato T, Vigorito R, Ruggirello M, Greco FG, Calareso G, Miliziano D, Rulli E, De Simone I, Torri V, de Braud FGM, Pasello G, De Placido P, Berardi R, Petrini I, Zucali P, Garassino MC, Lo Russo G. Proto C, et al. Among authors: de placido p. Ann Oncol. 2024 Sep;35(9):817-826. doi: 10.1016/j.annonc.2024.06.002. Epub 2024 Jun 8. Ann Oncol. 2024. PMID: 38857846 Free article. Clinical Trial.
Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis.
Valenza C, Saldanha EF, Gong Y, De Placido P, Gritsch D, Ortiz H, Trapani D, Conforti F, Cremolini C, Peters S, Mateo J, Subbiah V, Parsons HA, Partridge AH, Curigliano G. Valenza C, et al. Among authors: de placido p. Ann Oncol. 2025 Jul;36(7):726-736. doi: 10.1016/j.annonc.2025.03.019. Epub 2025 Apr 3. Ann Oncol. 2025. PMID: 40187491
Ductal Carcinoma In Situ.
Bychkovsky BL, Myers S, Warren LEG, De Placido P, Parsons HA. Bychkovsky BL, et al. Among authors: de placido p. Hematol Oncol Clin North Am. 2024 Aug;38(4):831-849. doi: 10.1016/j.hoc.2024.05.014. Hematol Oncol Clin North Am. 2024. PMID: 38960507 Review.
Mechanisms of resistance to mTOR inhibitors.
Formisano L, Napolitano F, Rosa R, D'Amato V, Servetto A, Marciano R, De Placido P, Bianco C, Bianco R. Formisano L, et al. Among authors: de placido p. Crit Rev Oncol Hematol. 2020 Mar;147:102886. doi: 10.1016/j.critrevonc.2020.102886. Epub 2020 Jan 29. Crit Rev Oncol Hematol. 2020. PMID: 32014673 Review.
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D. Schettini F, et al. Among authors: de placido p. Cancer Treat Rev. 2022 Dec;111:102468. doi: 10.1016/j.ctrv.2022.102468. Epub 2022 Sep 28. Cancer Treat Rev. 2022. PMID: 36202026 Free article.
Multidisciplinary approach for rare thoracic tumors during COVID-19 pandemic.
Pietroluongo E, De Placido P, Picozzi F, Morra R, Tortora M, Del Deo V, Montella L, Palmieri G, Buonomo AR, De Placido S, Gentile I, Giuliano M. Pietroluongo E, et al. Among authors: de placido p. Mediastinum. 2022 Jun 14;7:8. doi: 10.21037/med-21-47. eCollection 2023. Mediastinum. 2022. PMID: 36926294 Free PMC article. No abstract available.
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, De Laurentiis M, Thomas G, De Placido P, Arpino G, De Placido S, Cristofanilli M, Giordano A, Puglisi F, Pistilli B, Prat A, Del Mastro L, Venturini S, Generali D. Giuliano M, et al. Among authors: de placido p. Lancet Oncol. 2019 Oct;20(10):1360-1369. doi: 10.1016/S1470-2045(19)30420-6. Epub 2019 Sep 4. Lancet Oncol. 2019. PMID: 31494037
67 results